购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

产品编号 TMPK-01507

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

产品编号 TMPK-01507
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
规格价格库存数量
100 μg¥ 12,6005日内发货
1 mg¥ 84,0005日内发货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品信息

生物活性
Immobilized HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR at 1μg/ml (100μl/well) on the plate. Dose response curve for Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His Tag with the EC50 of 51.5ng/ml determined by ELISA.
产品描述
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
种属
Human
表达系统
HEK293 Cells
标签C-His-Avi
蛋白编号AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK
别名
RASK2,RALD,NS3,NS,MHC,K-RAS4B,K-RAS4A,K-RAS2B,K-RAS2A,KRAS2,KRAS1,K-Ras 2,KRAS,KI-RAS,GTPase Kras,C-K-RAS,CFC2
蛋白构建
Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M) and VVVGADGVGK peptide. Tetramer is assembled by biotinylated monomer and streptavidin.
蛋白纯度
> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
内毒素< 1 EU/μg by the LAL method.
缓冲液Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
复溶方法
Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
存储
Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

计算器

  • 复溶 计算器
  • 重组蛋白稀释 计算器
  • 比活力 计算器

技术支持

请阅读 重组蛋白用户指南 了解更多具体信息.